Brilinta Tablets 60mg/90mg Clinical Experience Investigation
Latest Information Update: 11 Nov 2024
Price :
$35 *
At a glance
- Drugs Ticagrelor (Primary)
- Indications Acute coronary syndromes; Myocardial infarction
- Focus Adverse reactions; Therapeutic Use
- Acronyms BRLCEIACS/OMI
- Sponsors AstraZeneca
- 07 Nov 2024 Status changed from active, no longer recruiting to completed.
- 01 Mar 2024 Status changed from recruiting to active, no longer recruiting.
- 16 Jun 2020 Planned End Date changed from 28 Jun 2024 to 30 Mar 2028.